WallStreetZenWallStreetZen

NASDAQ: INVA
Innoviva Inc Stock

$15.35-0.02 (-0.13%)
Updated Feb 28, 2024
INVA Price
$15.35
Fair Value Price
$17.99
Market Cap
$983.73M
52 Week Low
$10.64
52 Week High
$16.87
P/E
18.95x
P/B
1.57x
P/S
2.91x
PEG
N/A
Dividend Yield
N/A
Revenue
$290.43M
Earnings
$49.88M
Gross Margin
86.4%
Operating Margin
29.42%
Profit Margin
17.2%
Debt to Equity
0.89
Operating Cash Flow
$117M
Beta
0.8
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A

INVA Overview

Innoviva, Inc. engages in the development and commercialization of pharmaceuticals in the United States and internationally. Its products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA), umeclidinium bromide (UMEC), with a LABA, and VI; and TRELEGY ELLIPTA, a once-daily combination medicine consisting of an ICS, LAMA, and LABA. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. The company has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.

Zen Score

Industry Average (22)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how INVA scored across 38 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

INVA ($15.35) is undervalued by 14.66% relative to our estimate of its Fair Value price of $17.99 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
INVA ($15.35) is not significantly undervalued (14.66%) relative to our estimate of its Fair Value price of $17.99 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
INVA was unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 35 more INVA due diligence checks available for Premium users.

Be the first to know about important INVA news, forecast changes, insider trades & much more!

INVA News

Valuation

INVA fair value

Fair Value of INVA stock based on Discounted Cash Flow (DCF)
Price
$15.35
Fair Value
$17.99
Undervalued by
14.66%
INVA ($15.35) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
INVA ($15.35) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
INVA was unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

INVA price to earnings (PE)

For valuing profitable companies with steady earnings
Company
18.95x
Industry
13.96x
Market
35.52x
INVA is poor value based... subscribe to Premium to read more.
P/E vs Industry Valuation
INVA is good value based... subscribe to Premium to read more.
P/E vs Market Valuation

INVA price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
1.57x
Industry
6.14x
INVA is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

INVA's financial health

Profit margin

Revenue
$67.3M
Net Income
$82.0M
Profit Margin
122%
INVA's Earnings (EBIT) of $85.44M... subscribe to Premium to read more.
Interest Coverage Financials
INVA's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$1.2B
Liabilities
$560.6M
Debt to equity
0.89
INVA's short-term assets ($305.00M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
INVA's long-term liabilities ($524.43M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
INVA's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
INVA's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
$43.9M
Investing
-$25.9M
Financing
-$11.1M
INVA's operating cash flow ($116.71M)... subscribe to Premium to read more.
Debt Coverage Financials

INVA vs Biotech Stocks

TickerMarket Cap1d %P/EP/B
INVA$983.73M-0.13%18.95x1.57x
CABA$987.68M-5.22%-13.48x6.14x
EYPT$977.37M-3.45%-10.41x16.67x
PHVS$992.21M-0.98%-7.57x6.16x
SLN$992.44M+0.59%N/A39.70x

Innoviva Stock FAQ

What is Innoviva's quote symbol?

(NASDAQ: INVA) Innoviva trades on the NASDAQ under the ticker symbol INVA. Innoviva stock quotes can also be displayed as NASDAQ: INVA.

If you're new to stock investing, here's how to buy Innoviva stock.

What is the 52 week high and low for Innoviva (NASDAQ: INVA)?

(NASDAQ: INVA) Innoviva's 52-week high was $16.87, and its 52-week low was $10.64. It is currently -8.98% from its 52-week high and 44.27% from its 52-week low.

How much is Innoviva stock worth today?

(NASDAQ: INVA) Innoviva currently has 64,086,675 outstanding shares. With Innoviva stock trading at $15.35 per share, the total value of Innoviva stock (market capitalization) is $983.73M.

Innoviva stock was originally listed at a price of $14.59 in Oct 5, 2004. If you had invested in Innoviva stock at $14.59, your return over the last 19 years would have been 5.19%, for an annualized return of 0.27% (not including any dividends or dividend reinvestments).

How much is Innoviva's stock price per share?

(NASDAQ: INVA) Innoviva stock price per share is $15.35 today (as of Feb 28, 2024).

What is Innoviva's Market Cap?

(NASDAQ: INVA) Innoviva's market cap is $983.73M, as of Feb 29, 2024.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Innoviva's market cap is calculated by multiplying INVA's current stock price of $15.35 by INVA's total outstanding shares of 64,086,675.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.